BioLineRx Ltd. (BLRX)
After hours:
| Previous Close | 0.3245 |
| Open | 0.3200 |
| Bid | 0.2240 x 200 |
| Ask | 0.3481 x 200 |
| Day's Range | 0.2621 - 0.3233 |
| 52 Week Range | 0.2600 - 1.8900 |
| Volume | |
| Avg. Volume | 575,306 |
| Market Cap | 22.232M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings Date | Nov 25, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.83 |
TipRanksBioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization agent indicated in combination with filgrastim for collection and subsequent autologous transplantation in patients with multiple myeloma. Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda across all indications, excluding solid tumo
PR NewswireBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. ("Ayrmid"), the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA®), BioLineRx's FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subs
